Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

ClinicalTrials.gov ID: NCT04588922

Public ClinicalTrials.gov record NCT04588922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML

Study identification

NCT ID: NCT04588922
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sellas Life Sciences Group; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Hematologic Malignancies

Interventions

SLS009 Drug
azacitidine Drug
venetoclax Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 9, 2021
Primary completion: Dec 29, 2026
Completion: Dec 30, 2027
Last update posted: Apr 30, 2026

2021 – 2027

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
O'Neal Comprehensive Cancer Center, University of Alabama	Birmingham	Alabama	35233	Recruiting
City of Hope - Phoenix	Goodyear	Arizona	85338	Recruiting
City of Hope National Medical Center	Duarte	California	91010	Recruiting
City of Hope - Atlanta	Newnan	Georgia	30265	Recruiting
City of Hope - Chicago	Zion	Illinois	60099	Recruiting
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	Terminated
Clinical Research Alliance, Inc.	Lake Success	New York	11042	Terminated
New York - Presbyterian Hospital	New York	New York	10032	Terminated
UNC School of Medicine, Division of Hematology	Chapel Hill	North Carolina	27599	Recruiting
Bon Secours St. Francis Cancer Center	Greenville	South Carolina	29607	Recruiting
Baylor Scott & White Health	Dallas	Texas	75246	Recruiting
MD Anderson	Houston	Texas	77091	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04588922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04588922 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →